Q1 2026 · 13F-HR
Vivo Capital, LLCholdings as filed
Filed 2026-05-15 · accession 0001213900-26-057929
The Brief · Vivo Capital, LLC · Q1 2026
AI · grounded in 13F
Vivo Capital, LLC closed its position in Cidara Therapeutics, Inc. CDTX, reducing its exposure by $211.3M. The fund also exited positions in Avadel Pharmaceuticals PLC AVDL and Zenas Biopharma Inc ZBIO, which decreased its holdings by $57.8M and $31M respectively. On the buy side, the fund established new positions in Sensei Biotherapeutics Inc SNSE for $22.8M and Arrivent BioPharma Inc AVBP for $20.4M. Additionally, it increased its share count in Erasca Inc ERAS by 31.0%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 29479A108 | ERAS | Erasca Inc | $196.6M | 16.4% | 12,151,480 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines | $109.2M | 9.11% | 338,895 | Common | SOLE |
| 880881107 | 430 | Terns Pharmaceuticals Inc | $70.4M | 5.87% | 1,334,418 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $60.8M | 5.07% | 5,094,668 | Common | SOLE |
| 23306J309 | DBVT | DBV Technologies SA | $55.7M | 4.65% | 2,667,569 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics Inc | $50.5M | 4.21% | 9,545,466 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics Inc | $45.1M | 3.76% | 2,154,780 | Common | SOLE |
| 78397T202 | SABS | SAB Biotherapeutics Inc | $43.7M | 3.65% | 11,420,000 | Common | SOLE |
| 221015100 | CRVS | Corvus Pharmaceuticals Holdings | $41.0M | 3.43% | 2,805,816 | Common | SOLE |
| 10919W405 | DRUG | Bright Minds Biosciences Inc | $40.7M | 3.39% | 557,172 | Common | SOLE |
| P8696W104 | SVA | Sinovac Biotech Ltd. | $38.2M | 3.19% | 5,903,000 | Common | SOLE |
| 252828108 | DNTH | Dianthus Therapeutics Inc | $29.7M | 2.48% | 353,998 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $28.2M | 2.36% | 1,557,466 | Common | SOLE |
| 00370M103 | ABVX | Abivax SA - ADR | $26.7M | 2.23% | 239,539 | Common | SOLE |
| 603380205 | NERV | Minerva Neurosciences Inc | $26.0M | 2.17% | 4,322,747 | Common | SOLE |
| 00461U105 | ACRS | Aclaris Therapeutics, Inc. | $25.0M | 2.09% | 6,666,666 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $23.4M | 1.95% | 1,848,786 | Common | SOLE |
| 02157Q109 | ANRO | Alto Neuroscience Inc | $23.3M | 1.94% | 1,035,551 | Common | SOLE |
| 81728A207 | SNSE | Sensei Biotherapeutics Inc | $22.8M | 1.90% | 722,020 | Common | SOLE |
| 04272N102 | AVBP | Arrivent BioPharma Inc | $20.4M | 1.71% | 885,916 | Common | SOLE |
| 50180M108 | LBRX | LB Pharmaceuticals Inc | $19.7M | 1.65% | 800,000 | Common | SOLE |
| 922967104 | MANE | Veradermics Inc | $18.9M | 1.58% | 300,000 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 Therapeutics Inc | $18.7M | 1.56% | 4,246,568 | Common | SOLE |
| 61559X104 | MLTX | Moonlake Immunotherapeutics | $18.6M | 1.56% | 1,000,000 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics Inc | $17.2M | 1.43% | 1,612,903 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $16.3M | 1.36% | 422,300 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $12.9M | 1.08% | 8,671,797 | Common | SOLE |
| 90466Y202 | UNCY | Unicycive Therapeutics | $11.8M | 0.98% | 1,789,916 | Common | SOLE |
| 037326105 | ANTX | AN2 Therapeutics Inc | $10.8M | 0.90% | 3,153,640 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $10.0M | 0.84% | 671,843 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $9.9M | 0.82% | 294,909 | Common | SOLE |
| 29842P105 | EPRX | Eupraxia Pharmaceuticals Inc | $9.8M | 0.82% | 1,350,000 | Common | SOLE |
| 68277Q105 | OKUR | Onkure Therapeutics Inc | $8.0M | 0.67% | 1,927,710 | Common | SOLE |
| 86889P208 | SRZN | Surrozen Inc | $7.6M | 0.63% | 260,000 | Common | SOLE |
| 00166B105 | ALXO | ALX Oncology Holdings Inc | $6.4M | 0.53% | 3,184,713 | Common | SOLE |
| 61023L207 | MNPR | Monopar Therapeutics Inc | $5.0M | 0.41% | 90,500 | Common | SOLE |
| 713317105 | PEPG | Pepgen Inc | $4.1M | 0.34% | 2,325,000 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics Inc | $3.4M | 0.28% | 1,650,440 | Common | SOLE |
| 88032L605 | TENX | Tenax Therapeutics Inc | $3.3M | 0.28% | 208,333 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $3.3M | 0.27% | 166,288 | Common | SOLE |
| 45783C200 | TIL | Instil Bio Inc | $2.4M | 0.20% | 292,743 | Common | SOLE |
| 70261F202 | KTTA | Pasithea Therapeutics Corp | $1.6M | 0.13% | 2,100,000 | Common | SOLE |
| 20451W101 | CMPS | Compass Pathway PLC | $1.1M | 0.09% | 200,000 | Common | SOLE |
| 097702203 | BOLT | Bolt Therapeutics Inc | $292,553 | 0.02% | 72,414 | Common | SOLE |
| 74019P207 | DTIL | Precision Biosciences Inc | $25,713 | 0.00% | 4,675 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.